LA JOLLA, CA, April 30, 2024 – Enlaza Therapeutics, the first covalent biologic platform company, today announced a $100 million Series A financing. The financing will be used to further...
Afferent Pharmaceuticals named one of "The Hottest Startups of 2015" by Forbes
Afferent Pharmaceuticals named one of "The Hottest Startups of 2015" by Forbes.
© 2024 Pappas Capital, LLC. ALL RIGHTS RESERVED.